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Distal hereditary motor neuropathy (HMN) is a clinically and genetically heterogeneous group of disorders
affecting spinal a-motor neurons. Since 2001, mutations in six different genes have been identified for autosomal
dominant distal HMN; glycyl-tRNA synthetase (GARS), dynactin 1 (DCTN1), small heat shock 27kDa protein 1
(HSPB1), small heat shock 22kDa protein 8 (HSPB8), Berardinelli-Seip congenital lipodystrophy (BSCL2) and sena-
taxin (SETX). In addition a mutation in the (VAMP)-associated protein B and C (VAPB) was found in several
Brazilian families with complex and atypical forms of autosomal dominantly inherited motor neuron disease.
We have investigated the distribution of mutations in these seven genes in a cohort of 112 familial and isolated
patients with a diagnosis of distal motor neuropathy and found nine different disease-causing mutations in
HSPB8, HSPB1, BSCL2 and SETX in 17 patients of whom 10 have been previously reported. No mutations were
found in GARS, DCTN1 and VAPB. The phenotypic features of patients with mutations in HSPB8, HSPB1, BSCL2
and SETX fit within the distal HMN classification, with only one exception; a C-terminal HSPB1-mutation was
associated with upper motor neuron signs. Furthermore, we provide evidence for a genetic mosaicism in trans-
mitting anHSPB1mutation.This study, performed in a large cohort of familial and isolated distal HMN patients,
clearly confirms the genetic and phenotypic heterogeneity of distal HMN and provides a basis for the develop-
ment of algorithms for diagnostic mutation screening in this group of disorders.
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Introduction
Distal hereditary motor neuropathy (HMN), also known as
distal spinal muscular atrophy (SMA) or the spinal form of
Charcot–Marie–Tooth disease (CMT), covers a spectrum of
clinically and genetically heterogeneous diseases character-
ized by the selective involvement of motor neurons in the
peripheral nervous system. In contrast to proximal SMA,
distal HMN initially and predominantly affects the distal
limb muscles suggesting a length-dependent disease
mechanism affecting the longest motor axons first. The
vast majority of patients present a classical distal muscular
atrophy syndrome in the legs without clinical sensory loss.
The disease usually begins in childhood or adolescence and
starts with weakness and wasting of distal muscles of the
anterior tibial and peroneal compartments of the legs. Later
on, weakness and atrophy may expand to the proximal
muscles of the lower limbs and/or to the distal upper limbs.
However, in some patients and families the disease starts or
even predominates in the hands. Foot deformities (e.g. pes
cavus) are sometimes present. Based on clinical and elec-
trophysiological evidence, Dyck and Lambert (1968a, b)
postulated that distal HMN was a separate clinical and
genetic entity. Subsequently, a classification has been
proposed subdividing distal HMN in seven subtypes based
on age at onset, mode of inheritance, distribution of muscle
weakness and additional clinical features (Harding, 1993).
These subtypes were based on the description of a limited
number of patients in small families. Currently, with
detailed reports of a larger number of distal HMN families
including several large pedigrees and the identification of
gene defects, the phenotypes initially defined in this
classification could be confirmed at the molecular genetic
level. However, some clinical features were not included in
the original classification (e.g. pyramidal signs, congenital
onset and X-linked inheritance) and have resulted into
further diversification of the clinical spectrum of distal
HMN (Irobi et al., 2006).
Since 2001, eight genes have been identified for distal
HMN. Six genes have been associated with autosomal
dominant (AD) distal HMN: mutations in heat shock
27 kDa protein 1 (HSPB1) (Evgrafov et al., 2004) and heat
shock 22 kDa protein 8 (HSPB8) (Irobi et al., 2004b) are
found in families with distal HMN type II, mutations in
glycyl-tRNA synthetase (GARS) (Antonellis et al., 2003) are
associated with distal HMN type V, mutations in
Bernardinelli-Seip congenital lipodystrophy 2 (BSCL2)
(Windpassinger et al., 2004) cause distal HMN type V
and Silver syndrome, a single dynactin 1 (DCTN1) (Puls
et al., 2003) mutation was found in a family with adult-
onset motor neuron disease with breathing difficulties due
to vocal cord paralysis, and mutations in senataxin (SETX)
(Chen et al., 2004) are reported in families with an early-
onset distal HMN with pyramidal tract signs (juvenile
amyotrophic lateral sclerosis; ALS4). Furthermore, a muta-
tion was found in the VAMP-associated protein B and C
(VAPB) gene in Brazilian families with clinically diverse
motor neuron disorders, including atypical ALS with a slow
progression, typical ALS and SMA affecting mainly
proximal muscles (Nishimura et al., 2004). Currently, no
mutations in VAPB were reported in distal HMN patients
and families. Mutations causing autosomal recessive (AR)
distal SMA with respiratory distress (SMARD1; distal HMN
type VI) were described in the immunoglobulin -binding
protein 2a (IGHMBP2) (Grohmann et al., 2001) gene. In
addition, a mutation was recently found in the pleckstrin
homology domain-containing, family G member 5 gene
(PLEKHG5) in an autosomal recessive African family with
childhood onset and severe evolution (Maystadt et al., 2007).
The mutations in genes for distal HMN are listed in the
Inherited Peripheral Neuropathy Mutation Database (www.
molgen.ua.ac.be/-CMTMutations). Interestingly, most of
these genes encode for ubiquitously expressed proteins with
diverse cellular functions: protein translation and synthesis
(GARS, BSCL2), RNA/DNA metabolism (SETX, IGHMBP2),
axonal guidance and trafficking (HSP27, DCTN1,
PLEKHG5), cellular protection (HSP22, HSP27) and apop-
tosis (HSP27) (Van Den Bosch and Timmerman, 2006).
More insights into the role of these proteins in motor neuron
function will increase our knowledge of the pathophysiolo-
gical mechanisms underlying distal HMN.
With the identification of mutations in these genes it
also became apparent that mutations in the same gene
are associated with clinically separate disease entities, as
mutations in GARS (Sivakumar et al., 2005), HSPB1
(Evgrafov et al., 2004; Tang et al., 2005a) and HSPB8
(Irobi et al., 2004b; Tang et al., 2005b) have been found
both in familial and isolated patients with distal HMN and
hereditary motor and sensory neuropathy (HMSN; CMT)
phenotypes. However, there is scarce information about the
definite contribution of mutations in these genes in distal
HMN patients and about possible genotype–phenotype
correlations.
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In this study, we investigated a cohort of 112 familial and
isolated patients with a diagnosis of distal motor neuro-
pathy and determined the distribution of mutations in the
known genes associated with AD distal HMN. The cohort
included 10 index patients of families that have previously
been reported in manuscripts describing novel genes and
related phenotypes (Timmerman et al., 1992; De Jonghe
et al., 2002; Evgrafov et al., 2004; Irobi et al., 2004a, b). In
addition, we included the analysis of VAPB to investigate
whether the phenotype associated with mutations in VAPB
could be expanded to distal HMN.
Patients and Methods
Selection criteria
We selected in our patient database all distal HMN patients using
a pre-defined set of criteria. The clinical criteria for distal HMN
were previously designed by the European CMT Consortium (De
Jonghe et al., 1998) and include: slowly progressive muscle wasting
and weakness of predominantly the distal parts of the extremities
with variable severity. In contrast to the published criteria, we
included patients with pyramidal tract signs such as spastic gait,
brisk reflexes and Babinski signs since in the mean time it has
been demonstrated that these signs are common in distal HMN
patients with SETX and BSCL2 mutations. We excluded patients
presenting with predominant proximal muscle weakness, sensory
symptoms and signs, and significant central nervous system
involvement other than pyramidal tract signs. The clinical
diagnosis of distal HMN was confirmed by nerve conduction
studies and concentric needle electromyography (EMG) i.e.
normal sensory nerve conduction velocities (NCVs), normal or
slightly reduced motor NCVs and neurogenic alterations on needle
EMG examination.
Patient cohort
The cohort encompassed 112 index patients who were initially
referred for molecular genetic testing. Genomic DNA samples
were provided through Neurology Departments and
Neuromuscular Centres worldwide, with the majority from
European origin. For 57 out of 112 index patients, a dominant
inheritance pattern, based on a parent to child transmission, could
be determined. Twenty-one patients were referred as ‘isolated’
since they did not have a familial history of neuropathy in first
and second degree relatives. No family history was available for
the remaining 34 patients. Of 74 patients, we had information on
age at onset of the disease; in six patients the first symptoms
presented before the first year, in 19 patients the disease started in
the first decade of life, in 23 index patients the onset of disease
was within the second decade of life and in 26 patients the first
symptoms presented after the second decade of life. In 21 index
patients, pyramidal tract signs were present. Eight patients
presented bulbar symptoms including facial weakness, dysarthria,
dysphagia, vocal cord paralysis or breathing difficulties. We
obtained detailed electrophysiological information on 63 index
patients. The remaining patients had an electrophysiological
evaluation by their referring neurologist confirming a diagnosis
of distal HMN but no detailed data were available. All referring
neurologists were active in neuromuscular centres and were
familiar with the clinical and electrophysiological phenotype of
distal HMN. From all patients included in this cohort informed
consent was obtained by the referring physician.
Molecular genetic analysis
The coding regions and exon–intron boundaries of HSPB1,
HSPB8, BSCL2, GARS, SETX, DCTN1 and VAPB were PCR-
amplified using primer oligonucleotides designed with the Primer3
and SNPbox software tools (Supplementary Table 1) (Rozen and
Skaletsky, 2000; Weckx et al., 2004). PCR conditions are available
upon request. PCR products were cleaned up using the
Exonuclease I–Shrimp Alkaline Phosphatase enzyme (USB,
Cleveland, Ohio). Mutation screening was performed by direct
sequencing of the purified PCR fragments using the BigDye
Terminator v3.1 Cycle sequencing kit (Applied Biosystems, Foster
city, CA). Fragments were separated on an ABI 3730 automated
capillary DNA sequencer (Applied Biosystems). The resulting
sequences were aligned and analyzed with the SeqManII (DNAstar
Inc., Madison, WI) and the novoSNP program (Weckx et al.,
2005). The nucleotide numbering of the genes is relative to the
ATG translation initiation site with A as +1 of the corresponding
cDNA sequences (HSPB8: NM_014365.2; HSPB1: NM_001540.2;
BSCL2: NM_032667.7; GARS: NM_002047.2; SETX:
NM_015046.5; DCTN1: NM_004082.2; VAPB: NM_004738.3),
according to the nomenclature of DNA sequence variants
(http://www.hgvs.org/mutnomen). Sequence variants were con-
firmed by repeated PCR and bidirectional sequencing. Where
possible, segregation of the mutation with the disease phenotype
in the family was analysed.
Genotyping and paternity testing
Pyrosequencing with the PSQTMHS 96A System (Biotage AB,
Uppsala, Sweden) was performed to genotype the Pro182Leu
HSPB1-mutation. Primers for pyrosequencing were designed using
the SNP Primer Design software version 1.0.1 (Biotage AB
available upon request). Six informative short tandem repeats
(STRs), D7S2435, D7S2490 or D7S2518, D7S2470, D7S2421,
D7S669 and D7S2204, were used for segregation analysis at the
7q11–q21 locus (HSPB1). Genotype analysis of the 11q12–q14
locus (BSCL2) was performed with 13 STR markers: D11S1765,
D11S4076, D11S480, D11S4205, D11S1883, D11S987, CA9, CA10
(Magre et al., 2001), WP1, WP3, WP7, WP8 and WP9
(Windpassinger et al., 2004). Paternity was tested using 15
highly informative STRs distributed throughout the genome
(ATA38A05, D1S1646, D1S1653, D1S1360, D2S2256, D3S3037,
D4S2382, D4S3240, D7S509, D8S1759, D9S1118, D12S1056,
D12S2082, D16S2619 and GATA152H04). STRs were PCR-
amplified and PCR fragments were resolved on an ABI 3730
automated DNA sequencer. Genotypes were analysed using the
ABI Prism Genescan software (Applied Biosystems) and Trace
Inspector, an in-house developed software program (http://
www.vibgeneticservicefacility.be/).
Results
In 17 out of 112 index patients, we found sequence
variations causing pathogenic missense mutations in four
distal HMN genes: BSCL2, HSPB8, HSPB1 and SETX
(Table 1). These mutations were not detected in a panel of
400 control chromosomes. No mutations were found in
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Table 1 Clinical features of distal HMN patients with proven mutation
Patient Gene AA change Origin Inheritance AAO SAO ALE Walking Weakness
dist LL
Weakness
prox LL
Atrophy
dist LL
Pes
cavus
Reflexes
ank/knee
Weakness
dist UL
Atrophy
dist UL
Reflexes
UL
Additional
Features
References
CMT-206:IV.1 BSCL2 Asn88Ser Italy AD
penetrance#
inf Gait difficul-
ties, foot
deformities
42 Impaired,
improvement
after foot
surgery
P (0) A P P A/++ P (0) P  plantar
responses
neutral
(Irobi et al.,
2004a)
CMT-644:IV.3 BSCL2 Asn88Ser Serbia AD 45 Weakness of
right hand
55 Without any
support
P (3,4) A P (feet) P A/++ P (3/4) P (thenar,
interosseus I)
++ Novel family
CMT-745:III.1 BSCL2 Asn88Ser Poland AD 12 Weakness of
hands
15 Moderately
impaired
P A A A A/++ P P (thenar) ^ Novel family
CMT-I:III.14 BSCL2 Ser90Leu Belgium AD 30 Gait difficul-
ties, weakness
of hands
42 Spastic gait P (3) ^ P P +++/+++ P(3) P +++ plantar
responses
extension
(Irobi et al.,
2004a)
CMT-539:III.2 BSCL2 Ser90Leu The
Netherlands
AD 11 Weakness of
right hand
12 Spastic gait P (4) A A P ++/+++ A A ++ muscle tone
LL "
Novel family
CMT-716: I.2 BSCL2 Ser90Leu India AD 8 Walking diffi-
culties, atrophy
hand muscles
47 Spastic gait P (0,4) A P P A/+++ P (0,4) P (thenar,
hypothenar,
interosseus)
+++ spasticity LL,
knee clonus
Novel family
CMT-705:II.1 BSCL2 Ser90Leu Belgium AD 13 Gait difficul-
ties, weakness
of hands
15 Steppage P (4) P (5) A P A/+++ P (2/4) P (hands, R4L) A muscle tone
LL ", plantar
responses
extension
Novel family
CMT-734:II.1 BSCL2 Ser90Leu Switzerland de novo 5 Gait difficul-
ties, weakness
of hands
35 Spastic gait,
bilateral foot
drop
P A P P +++/+++ P (1/3/4) P (thenar,
interosseus I)
+++ muscle tone
LL "
Novel family
CMT-278:III.1 HSPB8 Lys141Glu Bulgaria AD 23 Distal weak-
ness of legs
52 Impaired,
walks with
canes
P (0) P (3) P P A/++ P (4) P (hands) ++ (Irobi et al.,
2004b)
CMT-M:IV.12 HSPB8 Lys141Asn Belgium AD 17 Gait difficulties 70 Steppage, bilat-
eral foot drop,
orthopaedic
shoes, walks
with cane
P P P ^ A/A P P A (Irobi et al.,
2004b)
CMT-196:VI.9 HSPB8 Lys141Asn Czech
Republic
AD 15 Distal weak-
ness of legs
40 Impaired,
walks with
canes
P (0) P (3) P A A/+ P (3) P (hands) ++ (Irobi et al.,
2004b)
PN-474:II.1 HSPB1 Arg127Trp Belgium AD 18 Cramps,
fasciculations
42 Moderately
impaired, no
aids
P (3,4) A P A A/++ A A ++ (Evgrafov et al.,
2004)
CMT-751:III.1 HSPB1 Arg127Trp France AD 35 Gait difficulties ^ Steppage, bilat-
eral foot drop
P A P P A/A P P ^ Novel family
CMT-263:IV.1 HSPB1 Thr151Ile Croatia AD 25 Fatigue, weak-
ness of legs
51 Steppage, no
aids
P (0) P (2/3) P P A/A P (2/3) P (hands) ++ (Evgrafov et al.,
2004)
CMT-391:II.1 HSPB1 Pro182Leu Austria Parental
mosaicism
5 Gait difficulties 16 ^ P A P P A/+++ P P ^ (Evgrafov et al.,
2004)
CMT-106:III.4 SETX Thr3Ile Austria AD 6 Gait difficulties 27 Impaired,
orthopaedic
shoes
P A P P +++/+++ P P +++ muscle tone
LL+UL ",
plantar
responses
extension
(Chen et al.,
2004)
CMT-61:III.4 SETX Arg2136His Belgium AD inf Gait difficulties 52 Steppage, bilat-
eral foot drop
P (0,1,4) A P A ++/++ P (2) P +++ (Chen et al.,
2004)
AA=amino acid; AD=autosomal dominant; AAO=age at onset (years); SAO=symptoms at onset; ALE=age at last exam (y); LL= lower limb; UL=upper limb; P=present;
A=absent; deep tendon reflexes: +=hypoactive; ++=normal; +++=brisk; "= increased; #=decreased; =unknown; reflexes ank/knee=ankle and knee deep tendon reflexes;
dist=distal; prox=proximal; inf= infancy; (MRC)=Medical Research Council scale for muscle strength, numbers between brackets indicate range of muscle weakness; R=right;
L= left.
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DCTN1, GARS and VAPB. Clinical and electrophysiological
data of the 17 index patients are summarized in Tables 1
and 2. The 17 index patients have an HMN phenotype with
distal weakness and atrophy. In seven patients with a BSCL2
mutation, the weakness was more pronounced in the hands
than legs. Age at onset was variable and upper motor neuron
signs were observed in eight patients. In most patients, normal
or slightly reduced motor NCVs were found with reduced
compound muscle action potential (CMAP) amplitudes.
Sensory NCVs were in the normal range or at the lower limit
and sensory nerve action potentials (SNAP) had normal
amplitudes. Two patients; CMT-705:II.1 and CMT-M:IV.12
had a slightly decreased sensory median NCV of 39.7 and
40.0 m/s respectively, due to a concomitant Carpal Tunnel
Syndrome. Recent re-evaluation showed a reduced Sural
nerve NCV of 36.2 m/s in CMT-263:IV.1, suggesting a
transition of distal HMN to HMSN-II, although the sensory
NCVs in the upper limbs remained normal (Table 2). The
absence of sensory response in the Sural nerve in patient
CMT-206:IV.1 may suggest a shift in diagnosis to HMSN-II as
well, which was recently described in the context of BSCL2
mutations (Table 2) (Bienfait et al., 2007). Although we do
not have evidence for a superimposed acquired sensory-
motor neuropathy, this observation, based on a single patient,
should be interpreted with caution. Of interest is that several
secondary patients in this family CMT-206 had a pure motor
neuropathy phenotype (Irobi et al., 2004a).
Mutations in BSCL2
The previously reported c.263A4G (Asn88Ser) and
c.269C4T (Ser90Leu) mutations were found in probands
of three and five distal HMN families, respectively
(Table 1). The segregation of the Asn88Ser mutation in
the family from Italy could be confirmed (Supplementary
Fig. 1) (Irobi et al., 2004a). In the family of Serbia,
however, the segregation of the pathogenic Asn88Ser
mutation could not be verified since the son CMT-
644:IV.1 was clinically and electrophysiologically normal.
This is possibly related to his relatively young age (27
years). In family CMT-745, no additional DNA samples of
the relatives were available to confirm the segregation of the
mutation. Comparison of the chromosome 11q haplotypes,
defining the BSCL2 locus of families with the Asn88Ser
mutation, i.e. CMT-206:IV.1 and CMT-644:IV.3, and of
families CMT-I:III.14, CMT-705:II.1 and CMT-539:III.2
with the Ser90Leu mutation suggested that these patients
are unlikely to be related (Fig. 1A). The Ser90Leu mutation
was absent in the healthy parents and sister of patient
CMT-734:II.1 (Supplementary Fig. 1). The paternity of this
patient was confirmed (data not shown), pointing that the
BSCL2-Ser90Leu mutation occurred de novo.
Mutations in HSPB8
Two mutations targeting the same lysine residue in HSPB8
were identified in three index patients (Table 1). The same
c.423G4C (Lys141Asn) mutation segregated in the unre-
lated Belgian and Czech families of patients CMT-M:IV.12
and CMT-196:VI.9, and the c.421A4G (Lys141Glu) muta-
tion was found in the Bulgarian patient CMT-278:III.1
(Irobi et al., 2004b). Segregation of this latter mutation was
confirmed in the affected son of the index patient
(Supplementary Fig. 1). The phenotype of family CMT-M
has previously been described in detail (Timmerman et al.,
1992, 1999).
Mutations in HSPB1
In this cohort, three different missense mutations in HSPB1
were found in four index patients (Table 1) (Evgrafov et al.,
2004). The unrelated index patients PN-474:II.1 and CMT-
751:III.1 belong to a Belgian and French family and share
the same missense mutation, c.379C4T (Arg127Trp),
targeting the highly conserved -crystallin domain of
HSPB1 (Figs. 1B and 2). Segregation of the c.452C4T
(Thr151Ile) mutation targeting the same -crystallin
domain in the Croatian family CMT-263 could be
confirmed in the index patient’s mother, an uncle and a
cousin (Supplementary Fig. 1). In the previously reported
patient CMT-391:II.1, belonging to an Austrian family, a
missense mutation (c.545C4T; Pro182Leu) was found in
the C-terminal IXI/V domain (Fig. 2). The younger affected
sib (CMT-391:II.3) showed a very similar disease course.
Remarkably, none of the asymptomatic parents of CMT-
391:II.1 did show the heterozygous HSPB1-mutation. False
paternity in this family was excluded (data not shown).
Interestingly, we detected very low levels of the mutant
allele in the electropherogram of one of the parents (CMT-
391:I.2) (Fig. 3A). The same low amount of mutant allele
was also observed using pyrosequencing, suggesting that a
fraction of this parent’s lymphocytes was heterozygous for
the mutation (Fig. 3B). By genotyping the five family
members with six STRs at the HSPB1 locus, we could
confirm the segregation of the mutant allele from the parent
to the affected children (Fig. 3C). These results demonstrated
that the parent CMT-391:I.2, who is clinically unaffected, is
most likely mosaic for the Pro182Leu-mutation.
Mutations in SETX
In two index patients, we identified a heterozygous missense
mutation in SETX: in the Austrian patient CMT-106:III.4 we
detected an N-terminal mutation, c.8C4T (Thr3Ile), and in
the Belgian patient CMT-61:III.4 a missense mutation,
c.6407G4A (Arg2136His), was found in the DNA/RNA
helicase domain of the protein (Table 1, Fig. 2). The families
to which the patients belong are described in De Jonghe et
al. (2002) and in Chen et al. (2004).
Discussion
Over the last 6 years, eight genes have been identified
in which mutations are associated with distal HMN.
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In this study, we investigated the relative contribution of
mutations in the six genes associated with AD distal
HMN: HSPB1, HSPB8, BSCL2, SETX, GARS, DCTN1 as well
as mutations in VAPB in a cohort of 112 index distal HMN
patients. In 17 index patients, we found disease-causing
mutations in four genes, i.e. three patients had an HSPB8
mutation, four patients showed an HSPB1 mutation,
BSCL2 mutations were found in eight probands and two
families had a SETX mutation. The 17 mutations represent a
mutation detection rate of 15% in the total cohort. The fact
that no mutations were identified in 40 patients with a family
history of distal HMN suggesting a dominant or autosomal
dominant inheritance pattern indicates that additional genes
must be involved in the pathogenesis of the disease. However,
when we only focus on patients with a dominant inheritance
the mutation yield increases to 30%. Moreover, if we
exclusively consider patients with pyramidal tract signs the
mutation rate rises to 38% (24% BSCL2, 9% SETX, 5%
HSP27). This finding underscores the involvement of central
motor tracts as a prominent aspect in several forms of distal
HMN. Pyramidal tract signs were also observed in several
other families with mutations in BSCL2 (Silver Syndrome)
(Auer-Grumbach et al., 2005).
Interestingly, the BSCL2 gene was found to be mutated
in 7% of our distal HMN patient cohort suggesting
that BSCL2 mutations are the most common causes of
distal HMN. The major contribution of BSCL2 mutations
to the aetiology of distal HMN was recently demonstrated
in a cohort of 33 patients diagnosed with distal HMN,
HMSN-II or Silver syndrome (Rohkamm et al., 2007) in
which 12% of patients had a mutation. The slightly higher
diagnostic yield of BSCL2 mutations found in that study
Table 2 Electrophysiological data of distal HMN patients with proven mutation
Patient Mutation Age R/L Median motor Ulnar motor Peroneal motor Tibial motor Median sensory Ulnar sensory Sural sensory
Amp CV Amp CV Amp CV Amp CV Amp CV Amp CV Amp CV
Normal
values!
4.0 49.0 4.0 49.0 3.0 41.0 3.0 41.0 7.0 46.0 2.0 46.0 1.0 44.0
CMT-206:IV.1 BSCL2
Asn88Ser
42 R ^ ^ 0.9 59.0 ^ 30.0 ^ ^ ^ ^ ^ ^ A A
CMT-644:IV.3 BSCL2
Asn88Ser
55 R 1.0 57.0 12.0 64.5 4.0 40.5 ^ ^ 30.0 59.0 24.0 66.5 10.0 54.0
CMT-745:III.1 BSCL2 15 R ^ ^ ^ ^ ^ 30.3 ^ ^ ^ ^ ^ ^ ^ ^
Asn88Ser L ^ ^ ^ ^ ^ 38.9 ^ ^ N N N N N N
CMT-I:III.14 BSCL2
Ser90Leu
42 R ^ ^ 6.1 62.0 1.6 65.0 ^ ^ 19.0 61.0 11.0 71.0 9.0 ^
CMT-539:III.2 BSCL2 12 R 0.2 ^ 0.3 ^ ^ ^ 6.7 42 20.8 54.0 20.6 50.0 ^ ^
Ser90Leu L ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ 12.0 45.0
CMT-716:I.2 BSCL2 46 R 0.3 29.9 1.3 53.3 1.4 46.7 ^ ^ 26.6 60.0 ^ ^ ^ ^
Ser90Leu L ^ ^ 0.3 48.8 0.8 34.6 ^ ^ ^ ^ 4.2 67.7 ^ ^
CMT-705:II.1 BSCL2
Ser90Leu
15 R 1.0 41.8 ^ ^ 1.5 38.1 4.3 40.5 28.0 39.7 ^ ^ ^ ^
CMT-734:II.1 BSCL2 35 R ^ ^ 8.0 66.7 ^ ^ 2.0 33.3 ^ ^ ^ ^ 7.1 64.3
Ser90Leu L ^ ^ 2.9 52.6 ^ ^ ^ ^ 7.0 53.0 12.9 61.5 6.5 54.9
CMT-278:III.1 HSPB8 40 R ^ 54.5 ^ 58.9 A A ^ ^ ^ ^ ^ ^ ^ ^
Lys141Glu L ^ ^ 31.6 56.0 A A ^ ^ 40.0 57.5 34.0 57.5 ^ ^
CMT-M:IV.12 HSPB8 NM R ^ 33.0 ^ 43.0 ^ ^ ^ ^ 14.0 40.0 10.0 46.0 ^ ^
Lys141Asn L ^ 38.0 ^ 38.0 ^ ^ ^ ^ ^ 42.0 ^ ^ ^ ^
CMT-196:VI.9 HSPB8 NM R ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ 8.0 46.0 10.0 46.0
Lys141Asn L 2.2 52.0 1.5 61.0 A A A A 16.0 52.0 ^ ^ 8.0 46.0
PN-474:II.1 HSPB1 44 R ^ ^ ^ ^ ^ ^ 0.3 26.0 ^ ^ ^ ^ ^ ^
Arg127Trp L 12.0 52.0 ^ ^ 0.7 33.0 A A ^ ^ ^ ^ 20.0 43.0
CMT-751:III.1 HSPB1
Arg127Trp
NM R N N ^ ^ A A A A ^ ^ ^ ^ 20.0 N
CMT-263:IV.1 HSPB1 51 R 4.0 55.8 2.0 49.4 ^ ^ ^ ^ 6.2 58.9 5.4 52.2 8.4 39.4
Thr151Ile 49 L 5.0 57.8 ^ ^ A A A A 8.0 60.6 ^ ^ 6.5 36.2
CMT-391:II.1 HSPB1
Pro182Leu
NM NM ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^
CMT-106:III.4 SETX NM R 5.0 52.0 7.0 53.0 0.3 32.0 11.0 31.0 7.9 35.0 ^ ^ 12.3 34.5
Thr3Ile L 10.0 49.0 8.5 50.0 0.2 31.0 10.5 33.0 ^ ^ ^ ^ ^ ^
CMT-61:III.4 SETX 52 R 0.7 27.0 0.6 30.0 0.7 33.0 ^ ^ 11.0 49.0 ^ ^ 11.0 48.0
Arg2136His L 0.7 35.0 1.2 26.0 ^ ^ ^ ^ 12.0 48.0 11.0 47.0 10.0 46.0
A=absent response; Age=age at examination; Amp=amplitude (motor: in mV; sensory: in mV); CV=conduction velocity (in m/s); =not
measured; NM=not mentioned; N=normal; R=right; L= left; Bold numbers=abnormal values.
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may be explained by the selective inclusion of distal
HMN patients with prominent hand muscle weakness.
Intriguingly, only two different BSCL2 mutations have been
reported so far. It is clear from our and previous studies
that both mutations represent mutational hot-spots since
they can arise independently in families and can occur
de novo. A broad spectrum of phenotypes is associated with
mutations in BSCL2 (Irobi et al., 2004a; Auer-Grumbach
et al., 2005). The detailed clinical and electrophysiological
observations within a single large Austrian family with the
Asn88Ser mutation enabled Auer-Grumbach et al. (2005) to
delineate six endophenotypes ranging from asymptomatic
individuals to Silver syndrome and spastic paraplegia.
A similar broad variability was seen in the clinical presenta-
tion of our patients with BSCL2 mutations. The disease
onset varied from infancy in patients CMT-206:IV.1,
CMT-716:I.2 (8 years) and CMT-734:II.1 (5 years) to
late-onset in patient CMT-644:IV.3 (45 years), and the
common presenting symptoms were atrophy and weakness
of hand muscles and/or gait difficulties. The clinical pre-
sentation of the index patients with an Asn88Ser mutation
consists of prominent distal muscle atrophy in the upper
Fig. 1 Haplotype/genotype analysis of chromosome 11q markers in patients with a BSCL2-ser90Leu and BSCL2-Asn88Ser mutation
(A) and 7q markers with a HSPB1-Arg127Trp mutation (B). The disease segregating haplotypes are shown.The haplotype phase of
patients CMT-716:I.2 and CMT-745:III.1 could not be determined.The alleles of the STRs are sized in base pairs (bp). The position of the
markers is according to the reference assembly of NCBI.
Fig. 2 Schematic presentation of protein structures of HSPB8, HSPB1, seipin and senataxin. The known and putative protein domains are
shown. Mutations found in this study are indicated with an arrow.TM=transmembrane; AA=amino acids; NLS=nuclear localization
signal.
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Fig. 3 Parental mosaicism for HSPB1-Pro182Leu in family CMT-391. Electropherograms (A) and pyrosequencing profiles (B) show very low levels of mutant allele (arrows) in the parent
(I.2). The mutant allele is boxed. (C) Segregation analysis of chromosome 7 STRs at the HSPB1 locus in family CMT-391. Symbols: diamond=gender status is masked for confidentiality
reasons, black filled symbol=affected, empty symbol=unaffected, symbol filled with ‘L’=parental mosaicism.
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limbs and to a variable degree in the lower limbs without
clear pyramidal tract signs. This is compatible with the
distal HMN type V phenotype. The phenotype of four of
the five index patients with a Ser90Leu mutation was
dominated by prominent amyotrophy of the intrinsic hand
muscles in association with marked spasticity in the lower
limbs and the presence of additional pyramidal tract
signs. This corresponds to the Silver syndrome phenotype.
Based on these interfamilial phenotypic features, it seems
that the BSCL2-Ser90Leu mutation is correlated with a
pronounced spasticity in the lower limbs and additional
upper motor neuron signs. This marked phenotypic
variation between the two BSCL2 mutations has also been
described in earlier reports (Silver 1966a, b; Auer-
Grumbach et al., 2005; van de Warrenburg et al., 2006;
Bienfait et al., 2007). Why distinct mutations in BSCL2
tend to result in different clinical outcomes remains
unclear, moreover since both mutations target the same
N-glycosylation motif of the seipin protein (Windpassinger
et al., 2004).
Pyramidal tract signs and an early disease onset were also
variably present in the two index patients (CMT-61:III.1
and CMT-106:III.1) with a SETX mutation, which under-
scores the involvement of the central nervous system in this
distal HMN subtype. Currently, only three heterozygous
mutations in SETX have been reported so far to be
associated with motor neuron disease (Chen et al., 2004).
A similar phenotype was found in the patient with the
C-terminal HSPB1-Pro182Leu mutation. The phenotype
associated with this mutation consisted of foot deformity
and gait abnormalities in early infancy (5 years) and the
presence of brisk knee tendon reflexes. With disease
progression the patient CMT-391:II.1 showed marked
distal muscle weakness in upper and lower limbs. A
mutation targeting the same C-terminal amino acid,
Pro182Ser, was previously reported in a Japanese patient
with distal HMN (Kijima et al., 2005). Similar to our
patient, the disease in this patient started in early
childhood; however, no upper motor neuron signs were
reported. Mutations in the C-terminal part of HSPB1 seem
to cause a more severe early-onset neuropathy than
mutations in the conserved -crystallin domain of the
HSPB1 protein (Arg127Trp and Thr151Ile) found in three
unrelated index patients with a classic adult-onset distal
motor neuropathy. The phenotype in these three patients
clearly resembles distal HMN type II.
The same homogeneous juvenile to adult-onset distal
HMN type II phenotype was found in the three patients
with an HSPB8-mutation targeting an identical lysine
residue. The HSPB8-Lys141Asn and the HSPB1-Arg127Trp
mutations were also reported in Chinese families presenting
mild sensory symptoms that were diagnosed with HMSN-II
(Tang et al., 2005b). It is likely that the disease in these
HMSN-II families represents a phenotypic variant of the
clinical continuum associated with -crystallin mutations
and that a diagnosis of HMSN-II rather than distal HMN
was prompted by the presence of more pronounced sensory
symptoms. Except for an impaired vibration sense in some
elderly patients, no sensory losses were noted in the studied
patients with an HSPB8 mutation. However, the presence of
mild sensory deficits during a more recent re-evaluation in
patient CMT-263:IV.1 (with the Thr151Ile mutation in
HSPB1) illustrates the clinical overlap between distal HMN
and HMSN-II (Table 2).
Another peculiar finding in this study was the evidence
of a parental mosaicism transmitting the HSPB1-Pro182Leu
mutation. A possible mosaicism was suspected since the
affected proband’s sib carried the same mutation, while the
unaffected parents were negative for the mutation on
standard sequencing. The absence of the disease in the
mosaic parent is likely the result of the very low amount of
mutant protein in the peripheral nervous system. The
occurrence of gonadal mosaicism was also considered, but
not examined, for a ‘de novo’ BSCL2 mutation in two sibs
of a Korean family with Silver syndrome and distal HMN
(Cho et al., 2007). These findings prove for the first time
the occurrence of genetic mosaicism in distal HMN. The
possibility of mosaicism even in sporadic distal HMN
patients has important implications for genetic counselling.
We did not detect disease-causing mutations in GARS,
which was somewhat unexpected since recently within a
cohort of 100 patients presenting inherited or sporadic
lower motor neuron degeneration, three different mutations
were found in one distal HMN type V family and two
families presenting distal HMN with lower limb predomi-
nance (James et al., 2006).
No mutations in DCTN1 were detected. Until now, only
one mutation in DCTN1 is described in a family with distal
spinal and bulbar muscular atrophy (Puls et al., 2003,
2005). No patients with a similar phenotype were included
in the cohort, probably explaining the absence of DCTN1
mutations and indicating that mutations in DCTN1 are
associated with a distinct and unique form of motor
neuron disease.
In this study, we also included the analysis of VAPB to
investigate whether the phenotype associated with the
Pro56Ser mutation in VAPB, found in several Brazilian
families with diverse forms of motor neuron disorders,
could be expanded to distal HMN. We did not detect the
Pro56Ser or other VAPB mutations in the cohort which
mainly consisted of European patients, suggesting that
mutations in this gene are probably not associated with
distal HMN.
In summary, we examined the distribution of mutations
in genes associated with AD distal HMN in a large group of
familial and sporadic patients. Our data highlight the
genetic and clinical heterogeneity of the disease. The
mutation rate in the studied genes was relatively low in
the total cohort, suggesting that other genes must be
involved in the pathomechanism of motor neuropathies.
We suggest that genetic testing of patients showing
prominent distal muscle atrophy in the upper limbs with
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a variable degree of upper motor neuron signs should start
with BSCL2, since the yield of mutations in BSCL2 within
our distal HMN cohort is 7%. Overall, the clinical
phenotype of patients with a known gene defect fit in the
proposed distal HMN classification by Irobi (2004), which
is based on the initial clinical distal HMN classification
system of Harding (1993) (Irobi et al., 2006). This study
underscores the involvement of central motor tracts in
distal HMN associated with mutations in BSCL2, SETX as
well as HSPB1. In addition, we provide evidence for a
genetic mosaicism in transmitting an HSPB1 mutation. In
genetic counselling, it might be important to consider
parental mosaicism even in sporadic distal HMN patients.
Additional descriptions of distal HMN families and patients
with a known genetic defect are needed to further organize
and refine the existing classification and to get more insight
into the molecular basis of these disorders.
Supplementary material
Supplementary material is available at Brain online.
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